Quantcast
Last updated on April 20, 2014 at 8:28 EDT

Latest Mitral regurgitation Stories

2012-05-15 06:29:21

NATICK, Mass., May 15, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announces results from the REPRISE I feasibility trial, which evaluated the acute safety of the Lotus(TM) Aortic Valve System in patients with severe aortic valve disease. The Lotus Aortic Valve System is the first transcatheter aortic valve replacement (TAVR) device of its kind that is designed to minimize aortic regurgitation (leaking) and is both fully repositionable and retrievable prior to release....

2012-05-14 02:27:14

--Presentations will Highlight Promising Results from Animal Studies-- TSX Venture Exchange: NVC VANCOUVER, May 14, 2012 /PRNewswire/ - Neovasc Inc. (TSXV: NVC), a developer of novel technologies to treat vascular disease, today announced that its Tiara(TM) technology under development for the transcatheter treatment of mitral valve disease will be featured in three scientific sessions at EuroPCR 2012, the annual meeting of the European Association for Percutaneous Cardiovascular...

2012-05-10 20:23:10

Patients with mitral regurgitation, a type of valvular heart disease common in the elderly, are living longer after surgery, Yale School of Medicine researchers report in the journal Circulation: Cardiovascular Quality and Outcomes. Surgery that replaces or repairs the mitral valve remains the definitive therapy for symptomatic mitral regurgitation, but surgery carries considerable risks of mortality and complications such as infection and renal failure. Led by John A. Dodson, M.D., a...

2012-05-10 10:25:17

LAS VEGAS, May 10, 2012 /PRNewswire/ -- An investigational therapy derived from a patient's own bone marrow stem cells improves heart function in some patients with progressive heart failure due to dilated cardiomyopathy (DCM), according to the results of a Phase 2a study presented today as a late-breaking clinical trial at the SCAI 2012 Scientific Sessions. Ixmyelocel-T is developed by culturing a patient's bone marrow for 12 days to increase the numbers of immune cells including...

2012-03-20 02:24:44

ABBOTT PARK, Ill., March 20, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) today announced the company's schedule of key presentations at the American College of Cardiology's (ACC) 61st Annual Scientific Session and i2 Summit 2012, to be held March 24 - 27 in Chicago. Presentations will include the following: data on patients at high surgical risk treated with the investigational MitraClip® system, an innovative catheter-based device for mitral valve repair; and two-year clinical...

2012-03-08 09:10:00

TSX Venture Exchange: NVC VANCOUVER, March 8, 2012 /PRNewswire/ - Neovasc Inc. (TSXV: NVC), a developer of novel technologies used to treat vascular disease, today announced that the company has been named Medical Device Company of the Year as part of the 2012 LifeSciences British Columbia Awards. Neovasc CEO Alexei Marko commented, "We are thrilled to be awarded this great honor by our peers and colleagues in the British Columbia life sciences community.  This has been a...

2012-03-01 01:52:53

Patients who had leaky mitral heart valves repaired along with bypass surgery had with healthier hearts than those who had bypass only, according to new research presented in the American Heart Association's Emerging Science Series webinar. The mitral valve separates the heart's left atrium (upper chamber) from the left ventricle (lower chamber). It has two flaps, or cusps, and if the flaps don't close properly, the valve will leak. "Many patients who need bypass surgery have mild to...

2012-02-22 06:28:00

TSX Venture Exchange: NVC VANCOUVER, Feb. 22, 2012 /PRNewswire/ - Neovasc Inc. (TSXV: NVC), a developer of novel technologies used to treat vascular disease, today announced that the company will participate in the Lazard Capital Markets Annual Medical Technology and Life Sciences/Tools Snowbird Conference.  The event is being held at the Snowbird Resort in Snowbird, UT February 29-March 2, 2012. The conference format consists of one-on-one meetings between participating...

2012-01-18 19:46:55

An estimated 1.6 million Americans suffer moderate to severe leakage through their tricuspid valves, which are complex structures that allow blood to flow from the heart's upper right chamber to the ventricle. If left untreated, severe leakage can affect an individual's quality of life and can even lead to death. A new study finds that the anatomy of the heart's tricuspid valve can be used to predict the severity of leakage in the valve, which is a condition called tricuspid regurgitation....

2012-01-04 06:28:00

-- Fifth Annual OneMedForum San Francisco Conference to Feature Emerging Healthcare and Life Science Companies -- TSX Venture Exchange: NVC VANCOUVER, Jan. 4, 2012 /PRNewswire/ - Neovasc Inc. (TSXV: NVC), a developer of novel technologies used to treat vascular disease, today announced that the company will present at the OneMedForum San Francisco 2012 Finance Conference on January 10, 2012 at 12 pm PST. The conference will be held at the Sir Francis Drake Hotel in San Francisco....